<div class="white-sheet">
	<div class="content-slide">

		<div class="title-bar red"></div>

		<div class="wrapper slide-2-3-1-2">

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>			
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>	
			</div>

			<div class="slide-title red two-line">
				Pathophysiology of acquired aplastic anaemia: T-cell-mediated destruction of bone marrow
			</div>


			<div class="content-container">

				<ul>
					<li><span>An immune response, led by an expanded cytotoxic T-cell population, targets HSCs and progenitor cells<sup>1</sup></span>
						<ul>
							<li><span>Directed at CD34+ cells<sup>1,2</sup></span></li>
							<li><span>T cells induce apoptosis and haematopoietic failure<sup>1</sup></span></li>
						</ul>
					</li>
					<li><span>Responsiveness of aplastic anaemia to immunosuppression has provided the strongest support for immune pathophysiology<sup>3</sup></span></li>
				</ul>

			</div>

		</div>

		<div class="information-overlay overlay">
			
			<header>Pathophysiology of acquired aplastic anaemia: T-cell-mediated destruction of bone marrow<sup>3</sup></header>
			
			<ul>
				<li><span>Observations that supported an underlying immune pathophysiology:</span>
					<ul>
						<li><span>Most patients show improvement after administration of antithymocyte globulins (ATGs), which causes transient T-cell depletion</span></li>
						<li><span>Relapsed aplastic anaemia responds to repeated immunosuppression</span>
							<ul>
								<li><span>For example restoration of blood counts to healthy levels after administration of low-dose ciclosporin (CsA)</span></li>
							</ul>
						</li>
						<li><span>The increasing proportion of responders as immunosuppressive regimens have intensified</span>
							<ul>
								<li><span>From early attempts with corticosteroids to the use of high-dose cyclophosphamide (Cy)</span></li>
							</ul>
						</li>
					</ul>
				</li>
				<li><span>Failure to respond to immunosuppression may indicate alternative pathophysiology, stem cell depletion, or immune mechanisms not susceptible to current therapies</span></li>
			</ul>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ol>
				<li class="navigateHref" data-navtarget="media/documents/Pallister&Watson-2011-Haematology-v2p17-27"><span>Young NS <i>et al. Curr Opin Hematol</i> 2008;15:162</span></li>
				<li class="navigateHref" data-navtarget="media/documents/Pallister&Watson-2011-Haematology-v2p17-27"><span>Brodsky RA & Jones RJ. <i>Lancet</i> 2005;365:1647</span></li>
				<li class="navigateHref" data-navtarget="media/documents/Pallister&Watson-2011-Haematology-v2p17-27"><span>Young NS. <i>Hematology Am Soc Hematol Educ Program</i> 2006;72</span></li>
				<li class="navigateHref" data-navtarget="media/documents/Pallister&Watson-2011-Haematology-v2p17-27"><span>Young NS & Maciejewski J. <i>N Eng J Med</i> 1997;336:1365 </span></li>
			</ol>

		</div>

	</div>
</div>